ClinicalTrials.gg
CompletedNCT00184717Updated Jul 7, 2017Results posted

Growth Hormone Treatment in Children Born Small for Gestational Age (SGA)

A Phase 3 interventional study of somatropin and somatropin in Foetal Growth Problem and Small for Gestational Age, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2017-07-07.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Aug 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Study summary

This study is conducted in Japan. The aim of this trial is to assess the efficacy and safety of somatropin in children born small for gestational age (SGA) in Japan.

In the main period, subjects will receive either active treatment for 104 weeks (two dosing regimens) or no treatment for 52 weeks followed by an extension period where subjects who received active treatment for 104 weeks (two years) will continue with the same treatment for further 156 weeks (three years) while those subjects who received no treatment for 52 weeks (one year) will be randomised to receive two dosing regimens for 208 weeks (four years). In total, subjects participate in trial for 260 weeks (five years).

Main period is registered internally at Novo Nordisk as GHLIQUID-1516 while the extension period is registered as GHLIQUID-1517.

02

Conditions studied

  • Foetal Growth Problem
  • Small for Gestational Age
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For MAIN period (GHLIQUID-1516):
  • Born small for gestational age (SGA) with birth weight and birth length below the 10th percentile for gestational age, and additional either birth length below or equal to -2.0 standard deviation score (SDS) or birth weight below or equal to -2.0 SDS for gestational age
  • Growth failure with height at -2.0 SDS or below for chronological age (CA)
  • Normal growth hormone (GH) production, defined as peak GH level > 10 ng/mL in one GH provocation test
  • For EXTENSION period (GHLIQUID-1517):
  • Subjects who completed the main period
  • Chronological age (CA) for boys at least 4 years, but maximum 11 years
  • Chronological age (CA) for girls at least 4 years, but maximum 10 years

Exclusion criteria

Exclusion Criteria:

  • Subjects with diabetes mellitus
  • Subjects suffering from
  • Several medical conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    0.033 mg / NN-220

    In the 156-week main period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime

    Drug: somatropin

  • Experimental
    0.067 mg / NN-220

    In the 156-week main period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime followed by a 104-week extension period where subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime

    Drug: somatropin

  • No intervention
    No treatment

    No somatropin (NN-220) treatment was given in the 52-week main period. Subjects was re-randomised to recive two dosing regimens (0.033 mg/kg/day or 0.067 mg/kg/day) in the 208-week extension period

  • Experimental
    No treatment --> 0.033 mg

    In the 208-week extension period, subjects received 0.033 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period

    Drug: somatropin

  • Experimental
    No treatment --> 0.067 mg

    In the 208-week extension period, subjects received 0.067 mg/kg/day somatropin (NN-220) s.c. (under the skin) injected at bedtime after having received no somatromin (NN-220) treatment in the 52-week main period

    Drug: somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years

    Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit

    Time frame: Week 0, week 260

  2. Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 208 - Subjects Received NN220 Treatment for 4 Years

    Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit

    Time frame: Week 0, week 208

Secondary outcomes

  1. Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 5 Years

    Yearly Height velocity SDS for chronological age were summarised and graphically presented

    Time frame: Weeks 0-260

  2. Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 4 Years

    Yearly Height velocity SDS for chronological age were summarised and graphically presented

    Time frame: Weeks 0-208

  3. Change in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years

    Bone age is measured as years and months (displayed as xx.x years). Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....

    Time frame: Week 0, week 260

  4. Change in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years

    Bone age is measured as years and months (displayed as xx.x years).Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....

    Time frame: Week 0, week 208

  5. Adverse Events - Subjects Received NN220 Treatment for 5 Years

    Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly

    Time frame: Weeks 0-260

  6. Adverse Events - Subjects Received NN220 Treatment for 4 Years

    Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly

    Time frame: Weeks 0-208

07

Results

Posted Jul 7, 2011

Participant flow

44 sites in Japan

Main Period (GHLIQUID-1516)
Participant flow — Main Period (GHLIQUID-1516)
Milestone0.033 mg / NN-2200.067 mg / NN-220No TreatmentNo Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Started39382100
Exposed to trial drug38382100
Completed36362000
Not completed32100
Extension Period (GHLIQUID-1517)
Participant flow — Extension Period (GHLIQUID-1517)
Milestone0.033 mg / NN-2200.067 mg / NN-220No TreatmentNo Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Started333301010
Completed2327075
Not completed106035

Outcome measures

PrimaryChange in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years

Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit

Time frame:
Week 0, week 260
Reported as:
Least squares mean · Standard Deviation Score (SDS)
Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years
Standard Deviation Score (SDS)0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Week 0-2.9488 ± 0.6368-2.9047 ± 0.6718——
Week 2601.2066 ± 0.11022.0247 ± 0.1083——
PrimaryChange in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 208 - Subjects Received NN220 Treatment for 4 Years

Height SDS for chronological age were derived as follow; {Height - mean (age, sex)}/ SD (age, sex), where mean (age, sex) and SD (age, sex) were mean and SD of height for corresponding chronological age and sex (data of those in 2000). Height SDS was calculated using mean of three height observations at corresponding visit

Time frame:
Week 0, week 208
Reported as:
Least squares mean · Standard Deviation Score (SDS)
Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 208 - Subjects Received NN220 Treatment for 4 Years
Standard Deviation Score (SDS)0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Week 0——-2.9603 ± 0.6689-2.7481 ± 0.3524
Week 208——1.0997 ± 0.24531.9151 ± 0.2275
SecondaryYearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 5 Years

Yearly Height velocity SDS for chronological age were summarised and graphically presented

Time frame:
Weeks 0-260
Reported as:
Mean · Standard Deviation Score (SDS)
Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 5 Years
Standard Deviation Score (SDS)0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Baseline, n=31, 34-1.6299 ± 0.9738-2.0303 ± 1.4527——
Week 52, n=29, 342.4717 ± 1.98484.7875 ± 1.9365——
Week 104, n=29, 321.1344 ± 1.27822.8877 ± 1.1272——
Week 156, n=25, 290.8015 ± 1.05832.1641 ± 1.5929——
Week 208, n=25, 280.3991 ± 1.30061.4724 ± 1.8696——
Week 260, n=23, 270.4612 ± 2.15580.7973 ± 2.1822——
SecondaryYearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 4 Years

Yearly Height velocity SDS for chronological age were summarised and graphically presented

Time frame:
Weeks 0-208
Reported as:
Mean · Standard Deviation Score (SDS)
Yearly Height Velocity SDS for Chronological Age - Subjects Received NN220 Treatment for 4 Years
Standard Deviation Score (SDS)0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Baseline, n=7,8——0.073 ± 1.5681-1.356 ± 0.708
Week 52, n=7, 8——2.1677 ± 0.615.9303 ± 1.2096
Week 104, n=6, 7——1.5268 ± 1.17153.3979 ± 1.0542
Week 156, n=6, 7——1.7617 ± 2.09562.3539 ± 1.3149
Week 208, n=6, 6——0.5475 ± 1.60552.199 ± 1.5973
SecondaryChange in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years

Bone age is measured as years and months (displayed as xx.x years). Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....

Time frame:
Week 0, week 260
Reported as:
Mean · years
Change in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years
years0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Change in Bone Age (Left Hand X-Ray) at Week 260 - Subjects Received NN220 Treatment for 5 Years5.79 ± 1.057.15 ± 1.05——
SecondaryChange in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years

Bone age is measured as years and months (displayed as xx.x years).Change in Bone age = Bone age at 52\*i weeks - Bone age at 52\*(i-1) weeks, i=1, 2, ....

Time frame:
Week 0, week 208
Reported as:
Mean · years
Change in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years
years0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
Change in Bone Age (Left Hand X-Ray) at Week 208 - Subjects Received NN220 Treatment for 4 Years——6.54 ± 1.265.6 ± 1.68
SecondaryAdverse Events - Subjects Received NN220 Treatment for 5 Years

Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly

Time frame:
Weeks 0-260
Reported as:
Number · Subjects
Adverse Events - Subjects Received NN220 Treatment for 5 Years
Subjects0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
AEs3134——
AEs possibly/probably related916——
SAEs24——
SecondaryAdverse Events - Subjects Received NN220 Treatment for 4 Years

Occurrence of Adverse Events (AEs) during treatment period (TEAEs), occurrence of possibly/probably related AEs during the treatment period, and occurrence of Serious Adverse Events (SAEs) during the treatment period. An AE is any undesirable medical event occurring to a subject in a clinical trial, whether or not related to the trial product(s). An SAE is an experience that at any dose is fatal, life-threatening, disabling or which results in the patient being hospitalised or, if already in hospital, that hospitalisation is prolonged, or ocurrence of congenital anomaly

Time frame:
Weeks 0-208
Reported as:
Number · Subjects
Adverse Events - Subjects Received NN220 Treatment for 4 Years
Subjects0.033 mg / NN-2200.067 mg / NN-220No Treatment --> 0.033 mgNo Treatment --> 0.067 mg
AEs——78
AEs possibly/probably relate——13
SAEs——01

Adverse events

Collected over The adverse events were collected from Aug 2004 to Dec 2009.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.033 mg / NN-220—12/31 (38.7%)31/31 (100%)
0.067 mg / NN-220—11/34 (32.4%)34/34 (100%)
0.033 mg / No Treatment—1/7 (14.3%)7/7 (100%)
0.067 mg / No Treatment—2/8 (25%)8/8 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
Event0.033 mg / NN-2200.067 mg / NN-2200.033 mg / No Treatment0.067 mg / No Treatment
Gastroenteritis viralInfections and infestations0/310/341/71/8
Adenoidal hypertrophyRespiratory, thoracic and mediastinal disorders1/310/340/71/8
ImpetigoInfections and infestations0/310/340/71/8
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders2/310/340/71/8
ConvulsionNervous system disorders2/310/340/70/8
Febrile convulsionNervous system disorders2/310/340/70/8
PneumoniaInfections and infestations2/311/340/70/8
StrabismusEye disorders2/311/340/70/8
Meningitis asepticInfections and infestations0/312/340/70/8
AsthmaRespiratory, thoracic and mediastinal disorders1/311/340/70/8
Most frequent other events
Showing 10 of 109
Most frequent other events
Event0.033 mg / NN-2200.067 mg / NN-2200.033 mg / No Treatment0.067 mg / No Treatment
InfluenzaInfections and infestations16/3125/346/74/8
NasopharyngitisInfections and infestations19/3127/346/75/8
BronchitisInfections and infestations14/3115/340/76/8
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders22/3122/345/76/8
Rhinitis allergicRespiratory, thoracic and mediastinal disorders8/318/341/75/8
Gastroenteritis viralInfections and infestations11/319/340/74/8
GastroenteritisInfections and infestations10/3114/340/71/8
PharyngitisInfections and infestations8/3114/342/73/8
ConjunctivitisEye disorders4/317/340/73/8
Otitis mediaInfections and infestations7/3112/341/73/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
Mean5.46 ± 1.375.15 ± 1.25.09 ± 1.375.27 ± 1.3
Sex: Female, Male
Sex: Female, Male(Participants)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
Female1114833
Male2420751
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
Hispanic or Latino0000
Not Hispanic or Latino35341584
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
American Indian or Alaska Native0000
Asian35341584
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
Japan35341584
Height
Height(cm)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
Mean96.19 ± 8.4894.57 ± 7.2894.42 ± 8.4895.22 ± 7.96
Body weight
Body weight(kg)0.033 mg / NN-2200.067 mg / NN-220No TreatmentTotal
Mean13.31 ± 2.5512.62 ± 1.8112.47 ± 2.9312.88 ± 2.36
08

Study locations

1 site
  • Novo Nordisk Investigational Site
    Tokyo, 1000005, Japan
09

References and documents

Publications

  • Tanaka T, Yokoya S, Seino Y, Togari H, Mishina J, Kappelgaard AM, Fujieda K. Long-term efficacy and safety of two doses of growth hormone in short Japanese children born small for gestational age. Horm Res Paediatr. 2011;76(6):411-8. doi: 10.1159/000334152. Epub 2011 Nov 29. PubMed 22156542 ↗
  • Kappelgaard AM, Kiyomi F, Horikawa R, Yokoya S, Tanaka T. The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age. Horm Res Paediatr. 2014;81(4):272-9. doi: 10.1159/000358196. Epub 2014 Feb 11. PubMed 24526136 ↗
  • Horikawa R, Tanaka T, Nishinaga H, Ogawa Y, Yokoya S. The influence of a long-term growth hormone treatment on lipid and glucose metabolism: a randomized trial in short Japanese children born small for gestational age. Int J Pediatr Endocrinol. 2016;2016:19. doi: 10.1186/s13633-016-0036-4. Epub 2016 Oct 26. PubMed 27799945 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2004 to primary completion in Mar 2006, 19 months.

Results were first posted in Jul 2011, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 16, 2005
StartActual
Aug 18, 2004
Primary completionActual
Mar 29, 2006
CompletionActual
Dec 28, 2009
Results first posted
Jul 7, 2011
Last update
Jul 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00184717
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
Aug 18, 2004
Primary completion
Mar 29, 2006
Completion
Dec 28, 2009
Results posted
Jul 7, 2011
Last update
Jul 7, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion